G. M. Hoffmann

Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44–GeparQuinto)

Gϋnter von Minckwitz, Gϋnter von Minckwitz, Sibylle Loibl et al. · Annals of Oncology · 2014 · 140 citations

Medicine, Oncology, Pharmacology +15

Cytoplasmic Poly(Adenosine Diphosphate–Ribose) Polymerase Expression Is Predictive and Prognostic in Patients With Breast Cancer Treated With Neoadjuvant Chemotherapy

Gϋnter von Minckwitz, Berit Müller, Sibylle Loibl et al. · Journal of Clinical Oncology · 2011 · 84 citations

Medicine, Molecular Biology, Oncology +17

Regional Monitoring for Disease Prediction and Optimization of Plant Protection Measuares: The IPM Wheat Model

Joseph‐Alexander Verreet, Holger Klink, G. M. Hoffmann · Plant Disease · 2000 · 70 citations

Agriculture, Agricultural Engineering, Agronomy +17

Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer—results from the GeparQuattro study (GBG 40)

Gϋnter von Minckwitz, Silvia Darb‐Esfahani, Sibylle Loibl et al. · Breast Cancer Research and Treatment · 2011 · 61 citations

Medicine, Oncology, Breast Oncology +14

Comparison of different approaches for assessment of HER2 expression on protein and mRNA level: prediction of chemotherapy response in the neoadjuvant GeparTrio trial (NCT00544765)

Aurelia Noske, Sibylle Loibl, Silvia Darb‐Esfahani et al. · Breast Cancer Research and Treatment · 2010 · 57 citations

Medicine, Cancer Biology, Oncology +17